Philip M. Arlen

Best Publications

• Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

  Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode

  1185
  Citations

• Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

  John L. Marshall;Robert J. Hoyer;Mary Ann Toomey;Kristen Faraguna

  531
  Citations

• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  431
  Citations

• A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

  Joseph Paul Eder;Philip W. Kantoff;Kristin Roper;GuangXian Xu

  425
  Citations

• Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

  John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  421
  Citations

• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  367
  Citations

• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

  James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  356
  Citations

• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa

  353
  Citations

• Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

  James Gulley;Alice P. Chen;William Dahut;Philip M. Arlen

  269
  Citations

• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  James L. Gulley;Philip M. Arlen;Kwong-Yok Tsang;Junko Yokokawa

  262
  Citations

• Cancer Vaccines: Moving Beyond Current Paradigms

  Jeffrey Schlom;Philip M. Arlen;James L. Gulley

  260
  Citations

• Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

  Ravi A Madan;Philip M Arlen;Mahsa Mohebtash;James W Hodge

  258
  Citations

• The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma

  M von Mehren;P Arlen;J Gulley;A Rogatko

  251
  Citations

• Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

  Junko Yokokawa;Vittore Cereda;Cinzia Remondo;James L. Gulley

  210
  Citations

• Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 Transgenes in patients with recurrent CEA-expressing adenocarcinomas

  Margaret von Mehren;Philip Arlen;Kwong Y. Tsang;André Rogatko

  207
  Citations

• Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

  Philip M. Arlen;Fernando Bianco;William L. Dahut;Anthony D'Amico

  190
  Citations

• Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy

  Ravi A. Madan;James L. Gulley;Jeffrey Schlom;Seth M. Steinberg

  172
  Citations

• A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

  Mahsa Mohebtash;Kwong-Yok Tsang;Ravi A. Madan;Ngar-Yee Huen

  151
  Citations

• Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

  Robert J. Lechleider;Philip M. Arlen;Kwong-Yok Tsang;Seth M. Steinberg

  151
  Citations

• Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy

  Philip M. Arlen;Lisa Skarupa;Mary Pazdur;Mahesh Seetharam

  144
  Citations